PKO BP BANKOWY Universal Pension Society JSC Purchases 32,000 Shares of Neurocrine Biosciences, Inc. $NBIX

PKO BP BANKOWY Universal Pension Society JSC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 23.1% during the second quarter, HoldingsChannel reports. The firm owned 170,802 shares of the company’s stock after acquiring an additional 32,000 shares during the quarter. Neurocrine Biosciences accounts for 8.2% of PKO BP BANKOWY Universal Pension Society JSC’s holdings, making the stock its 5th largest position. PKO BP BANKOWY Universal Pension Society JSC’s holdings in Neurocrine Biosciences were worth $28,786,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Geneos Wealth Management Inc. grew its position in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. DJE Kapital AG acquired a new position in Neurocrine Biosciences during the fourth quarter worth about $28,000. Basecamp Wealth Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at approximately $33,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after purchasing an additional 202 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 1.0%

Neurocrine Biosciences stock opened at $159.82 on Friday. The firm has a market capitalization of $16.25 billion, a price-to-earnings ratio of 23.43, a price-to-earnings-growth ratio of 0.58 and a beta of 0.39. The firm’s fifty day moving average price is $168.39 and its two-hundred day moving average price is $147.34. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NBIX shares. Weiss Ratings raised shares of Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. TD Cowen raised their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, July 31st. Citigroup boosted their price objective on Neurocrine Biosciences from $246.00 to $249.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Zacks Research cut Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $201.50.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the transaction, the insider directly owned 25,846 shares of the company’s stock, valued at $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the transaction, the insider directly owned 22,374 shares in the company, valued at approximately $3,495,266.28. This represents a 62.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 395,422 shares of company stock worth $62,448,693. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.